CLINICAL TRIALS PROFILE FOR ALDURAZYME
✉ Email this page to a colleague
All Clinical Trials for ALDURAZYME
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00144768 ↗ | A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | Completed | BioMarin/Genzyme LLC | Phase 4 | 2004-07-01 | The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate. |
| NCT00144768 ↗ | A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | Completed | Genzyme, a Sanofi Company | Phase 4 | 2004-07-01 | The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate. |
| NCT00215527 ↗ | Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I | Terminated | FDA Office of Orphan Products Development | Phase 1 | 2005-11-01 | The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD |
| NCT00215527 ↗ | Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I | Terminated | The Ryan Foundation | Phase 1 | 2005-11-01 | The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD |
| NCT00215527 ↗ | Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I | Terminated | University of California, Los Angeles | Phase 1 | 2005-11-01 | The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD |
| NCT00215527 ↗ | Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I | Terminated | Patricia I. Dickson, M.D. | Phase 1 | 2005-11-01 | The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD |
| NCT00638547 ↗ | Intrathecal Enzyme Replacement for Hurler Syndrome | Completed | Masonic Cancer Center, University of Minnesota | Phase 1 | 2008-01-02 | This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoing transplantation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ALDURAZYME
Condition Name
Clinical Trial Locations for ALDURAZYME
Trials by Country
Clinical Trial Progress for ALDURAZYME
Clinical Trial Phase
Clinical Trial Sponsors for ALDURAZYME
Sponsor Name
